Merck KGaA (XSWX:MER) Interest Expense: CHF-383 Mil (TTM As of Mar. 2026)


XSWX:MER Merck KGaA XSWX:MER
83 GF Score
Price CHF130.30
GF Value CHF125.76
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Interest Expense?

Merck KGaA XSWX:MER +4.03% 83 Interest Expense is CHF-383 Mil as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 83/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Merck KGaA's interest expense for the three months ended in Mar. 2026 was CHF -95 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-383 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Merck KGaA's Operating Income for the three months ended in Mar. 2026 was CHF 858 Mil. Merck KGaA's Interest Expense for the three months ended in Mar. 2026 was CHF -95 Mil. Merck KGaA's Interest Coverage for the quarter that ended in Mar. 2026 was 9.07. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Merck KGaA  (XSWX:MER) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Merck KGaA's Interest Expense for the three months ended in Mar. 2026 was CHF-95 Mil. Its Operating Income for the three months ended in Mar. 2026 was CHF858 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was CHF9,832 Mil.

Merck KGaA's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*858.294/-94.658
=9.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Merck KGaA Interest Expense Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Interest Expense Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -283.06 -231.91 -302.73 -272.62 -360.19

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.51 -74.10 -117.73 -96.11 -94.66
XSWX:MER
83GF Score
Merck KGaA XSWX:MER
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-383 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of CHF-383 Mil mean?
Merck KGaA (XSWX:MER) has a Interest Expense of CHF-383 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Interest Expense too high?
Merck KGaA's current Interest Expense is CHF-383 Mil. Overall, Merck KGaA has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Interest Expense compare to ZTS and UTHR?
Merck KGaA's Interest Expense of CHF-383 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Merck KGaA and its competitors. Merck KGaA's current Interest Expense is CHF-383 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Interest Expense of CHF-383 Mil. The stock's GF Value™ is CHF125.76, compared to a current price of CHF130.30 — trading 3.6% above its estimated fair value. The current Interest Expense is CHF-383 Mil. Merck KGaA's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Interest Expense is CHF-383 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of CHF130.30 is trading 3.6% above its estimated GF Value™ of CHF125.76.

Key valuation signals for XSWX:MER:

  • Interest Expense: CHF-383 Mil
  • GF Value™: CHF125.76 vs. price of CHF130.30 (3.6% above fair value)
  • GF Score™: 83/100 with 9 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
83GF Score

Get the complete analysis for XSWX:MER

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF130.30
Price
CHF125.76
GF Value